STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma PURPOSESTELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 as...

Eflornitina + lomustina duplica supervivencia libre de progresión y mejora supervivencia general en pacientes con astrocitoma grado 3 con mutación en IDH, luego de la radioterapia y temozolomida #eflornithine #astrocitoma ascopubs.org/doi/full/10....

Anaplastic Astrocytoma Market Expected to Experience Significant Growth by 2034 The Anaplastic Astrocytoma market is set to witness remarkable growth from 2025 to 2034, driven by increased awareness of therapies and diagnosis.

Anaplastic Astrocytoma Market Expected to Experience Significant Growth by 2034 #United_States #Las_Vegas #Eflornithine #Anaplastic_Astrocytoma #Zotiraciclib

Swissmedic Approves IFINWIL® for Children with High-Risk Neuroblastoma Norgine announces that Swissmedic has approved IFINWIL® for pediatric patients with high-risk neuroblastoma, marking a vital advancement in treatment options for children.

Swissmedic Approves IFINWIL® for Children with High-Risk Neuroblastoma #Switzerland #Eflornithine #Norgine #IFINWIL® #Ubxbridge

Norgine Advances Pediatric Oncology with Eflornithine Application to EMA Norgine has filed a marketing authorisation application for eflornithine to treat high-risk neuroblastoma, enhancing pediatric oncology care in Europe.

Norgine Advances Pediatric Oncology with Eflornithine Application to EMA #London #United_Kingdom #Eflornithine #Neuroblastoma #Norgine